메뉴 건너뛰기




Volumn 13, Issue 5, 2015, Pages 477-488

Evolocumab (AMG 145) for primary hypercholesterolemia

Author keywords

cardiovascular disease; evolocumab; hypercholesterolemia; LDL cholesterol; PCSK9

Indexed keywords

EVOLOCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; HYPOCHOLESTEROLEMIC AGENT; LIPID; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

EID: 84928639375     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1030395     Document Type: Review
Times cited : (55)

References (54)
  • 2
    • 4444382796 scopus 로고    scopus 로고
    • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study
    • Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
    • (2004) Lancet , vol.364 , pp. 937-952
    • Yusuf, S.1    Hawken, S.2    Ounpuu, S.3
  • 3
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 4
    • 7144250513 scopus 로고    scopus 로고
    • Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias
    • Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998;158:1253-61
    • (1998) Arch Intern Med , vol.158 , pp. 1253-1261
    • Buchwald, H.1    Varco, R.L.2    Boen, J.R.3
  • 5
    • 84923184260 scopus 로고    scopus 로고
    • Improve IT Investigators. IMPROVE-IT trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes
    • November 17. Chicago, IL; Abstract 2014
    • Cannon CP. Improve IT Investigators. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Presented at the American Heart Association Scientific Sessions, November 17, 2014. Chicago, IL; Abstract 2014
    • (2014) American Heart Association Scientific Sessions
    • Cannon, C.P.1
  • 6
    • 81355160365 scopus 로고    scopus 로고
    • Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy
    • Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-7
    • (2011) Circulation , vol.124 , pp. 2202-2207
    • Raal, F.J.1    Pilcher, G.J.2    Panz, V.R.3
  • 7
    • 79960539641 scopus 로고    scopus 로고
    • ESC/ EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European society of cardiology (esc) and the European atherosclerosis society (EAS)
    • European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G, et al. ESC/ EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (esc) and the European atherosclerosis society (EAS). Eur Heart J 2011;32:1769-818
    • (2011) Eur Heart J , vol.32 , pp. 1769-1818
    • European Association for Cardiovascular Prevention & Rehabilitation1    Reiner, Z.2    Catapano, A.L.3    De Backer, G.4
  • 8
    • 84897970506 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines
    • Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014;129:S1-45
    • (2014) Circulation , vol.129 , pp. S1-45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3
  • 9
    • 77950174523 scopus 로고    scopus 로고
    • Two years after molecular diagnosis of familial hypercholesterolemia: Majority on cholesterol-lowering treatment but a minority reaches treatment goal
    • Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010;5:e9220
    • (2010) PLoS One , vol.5 , pp. e9220
    • Huijgen, R.1    Kindt, I.2    Verhoeven, S.B.3
  • 10
    • 32444444724 scopus 로고    scopus 로고
    • Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO study
    • Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
    • (2005) Cardiovasc Drugs Ther , vol.19 , pp. 403-414
    • Bruckert, E.1    Hayem, G.2    Dejager, S.3
  • 12
    • 0037036822 scopus 로고    scopus 로고
    • ACC/AHA/NHLBI clinical advisory on the use and safety of statins
    • Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
    • (2002) J Am Coll Cardiol , vol.40 , pp. 567-572
    • Pasternak, R.C.1    Smith, S.C.2    Bairey-Merz, C.N.3
  • 13
    • 84927742065 scopus 로고    scopus 로고
    • Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
    • Epub ahead of print
    • Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015. [Epub ahead of print]
    • (2015) Eur Heart J
    • Stroes, E.S.1    Thompson, P.D.2    Corsini, A.3
  • 14
    • 0037417807 scopus 로고    scopus 로고
    • The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation
    • Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003;100:928-33
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 928-933
    • Seidah, N.G.1    Benjannet, S.2    Wickham, L.3
  • 15
    • 0037603589 scopus 로고    scopus 로고
    • Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    • Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
    • (2003) Nat Genet , vol.34 , pp. 154-156
    • Abifadel, M.1    Varret, M.2    Rabes, J.P.3
  • 16
    • 66349126280 scopus 로고    scopus 로고
    • PCSK9: A convertase that coordinates LDL catabolism
    • Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50(Suppl): S172-7
    • (2009) J Lipid Res , vol.50 , pp. S172-S177
    • Horton, J.D.1    Cohen, J.C.2    Hobbs, H.H.3
  • 17
    • 34548175537 scopus 로고    scopus 로고
    • Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
    • Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007;48:1488-98
    • (2007) J Lipid Res , vol.48 , pp. 1488-1498
    • Qian, Y.W.1    Schmidt, R.J.2    Zhang, Y.3
  • 18
    • 67649834056 scopus 로고    scopus 로고
    • A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
    • Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009;106:9820-5
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 9820-9825
    • Chan, J.C.1    Piper, D.E.2    Cao, Q.3
  • 19
    • 84868689211 scopus 로고    scopus 로고
    • Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    • Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900
    • (2012) N Engl J Med , vol.367 , pp. 1891-1900
    • Roth, E.M.1    McKenney, J.M.2    Hanotin, C.3
  • 20
    • 84904383126 scopus 로고    scopus 로고
    • Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study (NCT 01592240)
    • Abstr 1374
    • Ballantyne C, Neutel J, Cropp A, et al. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study (NCT 01592240). J Am Coll Cardiol 2014;63(Suppl):Abstr 1374
    • (2014) J Am Coll Cardiol , vol.63
    • Ballantyne, C.1    Neutel, J.2    Cropp, A.3
  • 21
    • 84868206496 scopus 로고    scopus 로고
    • Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins
    • Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-98
    • (2012) J Am Coll Cardiol , vol.60 , pp. 1888-1898
    • Dias, C.S.1    Shaywitz, A.J.2    Wasserman, S.M.3
  • 22
    • 84870478439 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study
    • Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17
    • (2012) Lancet , vol.380 , pp. 2007-2017
    • Giugliano, R.P.1    Desai, N.R.2    Kohli, P.3
  • 23
    • 84899633509 scopus 로고    scopus 로고
    • Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study
    • Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study. Circ J 2014;78:1073-82
    • (2014) Circ J , vol.78 , pp. 1073-1082
    • Hirayama, A.1    Honarpour, N.2    Yoshida, M.3
  • 24
    • 84892679366 scopus 로고    scopus 로고
    • Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
    • Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129:234-43
    • (2014) Circulation , vol.129 , pp. 234-243
    • Koren, M.J.1    Giugliano, R.P.2    Raal, F.J.3
  • 25
    • 84870494510 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study
    • Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380:1995-2006
    • (2012) Lancet , vol.380 , pp. 1995-2006
    • Koren, M.J.1    Scott, R.2    Kim, J.B.3
  • 26
    • 84869220345 scopus 로고    scopus 로고
    • Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
    • Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17
    • (2012) Circulation , vol.126 , pp. 2408-2417
    • Raal, F.1    Scott, R.2    Somaratne, R.3
  • 27
    • 84863494422 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial
    • Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36
    • (2012) Lancet , vol.380 , pp. 29-36
    • Stein, E.A.1    Gipe, D.2    Bergeron, J.3
  • 28
    • 84871326497 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial
    • Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506
    • (2012) JAMA , vol.308 , pp. 2497-2506
    • Sullivan, D.1    Olsson, A.G.2    Scott, R.3
  • 29
    • 84862219022 scopus 로고    scopus 로고
    • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease, SAR236553/ REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
    • McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease, SAR236553/ REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53
    • (2012) J Am Coll Cardiol , vol.59 , pp. 2344-2353
    • McKenney, J.M.1    Koren, M.J.2    Kereiakes, D.J.3
  • 30
    • 84891904473 scopus 로고    scopus 로고
    • Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor
    • Zhang Y, Eigenbrot C, Zhou L, et al. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem 2014;289:942-55
    • (2014) J Biol Chem , vol.289 , pp. 942-955
    • Zhang, Y.1    Eigenbrot, C.2    Zhou, L.3
  • 31
    • 84905001697 scopus 로고    scopus 로고
    • Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering
    • Mitchell T, Chao G, Sitkoff D, et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther 2014;350:412-24
    • (2014) J Pharmacol Exp Ther , vol.350 , pp. 412-424
    • Mitchell, T.1    Chao, G.2    Sitkoff, D.3
  • 32
    • 84928638304 scopus 로고    scopus 로고
    • Development of monthly to quarterly subcutaneous administration of RNAi therapeutics targeting the metabolic disease genes PCSK9, ApoC3 and ANGPTL3
    • Chicago, IL; Abstract 11936
    • Borodovsky A, Querbes W, Yucius K, et al. Development of monthly to quarterly subcutaneous administration of RNAi therapeutics targeting the metabolic disease genes PCSK9, ApoC3 and ANGPTL3. Presented at the American Heart Association Scientific Sessions, November 17, 2014. Chicago, IL; Abstract 11936
    • (2014) American Heart Association Scientific Sessions, November 17
    • Borodovsky, A.1    Querbes, W.2    Yucius, K.3
  • 33
    • 84904395849 scopus 로고    scopus 로고
    • LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: Results of a single ascending dose study
    • Abstr 1372
    • Stein E, Kasichayanula S, Turner T, et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol 2014;63(Supp): Abstr 1372
    • (2014) J Am Coll Cardiol , vol.63
    • Stein, E.1    Kasichayanula, S.2    Turner, T.3
  • 34
    • 84887164358 scopus 로고    scopus 로고
    • Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
    • Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128: 2113-20
    • (2013) Circulation , vol.128 , pp. 2113-2120
    • Stein, E.A.1    Honarpour, N.2    Wasserman, S.M.3
  • 36
    • 84921459685 scopus 로고    scopus 로고
    • Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50
    • (2015) Lancet , vol.385 , pp. 341-350
    • Raal, F.J.1    Honarpour, N.2    Blom, D.J.3
  • 38
    • 84921483643 scopus 로고    scopus 로고
    • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385: 331-40
    • (2015) Lancet , vol.385 , pp. 331-340
    • Raal, F.J.1    Stein, E.A.2    Dufour, R.3
  • 39
    • 84899846576 scopus 로고    scopus 로고
    • A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
    • Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19
    • (2014) N Engl J Med , vol.370 , pp. 1809-1819
    • Blom, D.J.1    Hala, T.2    Bolognese, M.3
  • 40
    • 84902142901 scopus 로고    scopus 로고
    • Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
    • Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2531-40
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2531-2540
    • Koren, M.J.1    Lundqvist, P.2    Bolognese, M.3
  • 41
    • 84900303213 scopus 로고    scopus 로고
    • Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
    • Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870-82
    • (2014) JAMA , vol.311 , pp. 1870-1882
    • Robinson, J.G.1    Nedergaard, B.S.2    Rogers, W.J.3
  • 42
    • 84902157271 scopus 로고    scopus 로고
    • Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
    • Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63: 2541-8
    • (2014) J Am Coll Cardiol , vol.63 , pp. 2541-2548
    • Stroes, E.1    Colquhoun, D.2    Sullivan, D.3
  • 43
    • 84927724948 scopus 로고    scopus 로고
    • Efficacy of evolocumab (AMG 145) in patients with PCSK9 gain-of-function mutations
    • Abstract
    • Harada-Shiba M, Kishimoto I, Makino H, et al. Efficacy of evolocumab (AMG 145) in patients with PCSK9 gain-of-function mutations. Atherosclerosis 235, e11. Abstract 2014
    • (2014) Atherosclerosis , vol.235 , pp. e11
    • Harada-Shiba, M.1    Kishimoto, I.2    Makino, H.3
  • 44
    • 84922670093 scopus 로고    scopus 로고
    • Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: Pooled analysis of 1359 patients in four phase 2 trials
    • Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014;35:2249-59
    • (2014) Eur Heart J , vol.35 , pp. 2249-2259
    • Stein, E.A.1    Giugliano, R.P.2    Koren, M.J.3
  • 47
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354: 1264-72
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, T.H.3    Hobbs, H.H.4
  • 48
    • 84872473017 scopus 로고    scopus 로고
    • PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
    • Postmus I, Trompet S, de Craen AJ, et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J Lipid Res 2013;54:561-6
    • (2013) J Lipid Res , vol.54 , pp. 561-566
    • Postmus, I.1    Trompet, S.2    De Craen, A.J.3
  • 49
    • 33748661502 scopus 로고    scopus 로고
    • Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
    • Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79:514-23
    • (2006) Am J Hum Genet , vol.79 , pp. 514-523
    • Zhao, Z.1    Tuakli-Wosornu, Y.2    Lagace, T.A.3
  • 50
    • 84906716305 scopus 로고    scopus 로고
    • Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society
    • Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart J 2014;35:2146-57
    • (2014) Eur Heart J , vol.35 , pp. 2146-2157
    • Cuchel, M.1    Bruckert, E.2    Ginsberg, H.N.3
  • 51
    • 84893647246 scopus 로고    scopus 로고
    • Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
    • Epub ahead of print
    • Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol 2014. [Epub ahead of print]
    • (2014) Eur J Prev Cardiol
    • Watts, G.F.1    Gidding, S.2    Wierzbicki, A.S.3
  • 52
    • 84890461947 scopus 로고    scopus 로고
    • Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society
    • Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-90a
    • (2013) Eur Heart J , vol.34 , pp. 3478-90a
    • Nordestgaard, B.G.1    Chapman, M.J.2    Humphries, S.E.3
  • 53
    • 77049105368 scopus 로고    scopus 로고
    • Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in the Netherlands
    • Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209:189-94
    • (2010) Atherosclerosis , vol.209 , pp. 189-194
    • Pijlman, A.H.1    Huijgen, R.2    Verhagen, S.N.3
  • 54
    • 84965048474 scopus 로고    scopus 로고
    • Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm
    • November 17. Chicago, IL; Abstract 20773
    • Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Presented at the American Heart Association Scientific Sessions, November 17, 2014. Chicago, IL; Abstract 20773
    • (2014) American Heart Association Scientific Sessions
    • Moriarty, P.M.1    Thompson, P.D.2    Cannon, C.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.